Chlormethine gel (Ledaga®). HTA ID: 23049

Assessment Status Rapid Review Complete
HTA ID 23049
Drug Chlormethine gel
Brand Ledaga®
Indication Chlormethine gel (Ledaga®) is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients.
Assessment Process
Rapid review commissioned 31/07/2023
Rapid review completed 20/09/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that chlormethine gel not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.